Breast cancer can spread to the lungs or to the space between the lung and the chest wall, making fluid build up around the lung. Symptoms can include shortness of breath, a cough that won’t go away, and chest pain. Some people lose their appetite, leading to weight loss. 7/8 Brain...
Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms. • ...
In cancer of the breast or prostate, cancer cells can remain dormant for years and even decades before recurring as metastatic disease.23 During this latent period, patients are considered to be disease-free due to the lack of any symptoms of illness and because they have no detectable ...
“This is an important day for the breast cancer community,” said Catherine Ormerod, Executive Vice President, Strategy and Mission, Living Beyond Breast Cancer. “With this approval, ENHERTU now provides a new treatment option for patients wi...
Patients should be assessed for signs of thyroid dysfunction prior to the initiation of CABOMETYX and monitored for signs and symptoms of thyroid dysfunction during CABOMETYX treatment. Thyroid function testing and management of dysfunction should be performed as clinically indicated. ...
Summary of recommendations: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (EWG) found that, for patients with metastatic colorectal cancer (mCRC) who are being considered for treatment with cetuximab or panitumumab, there is convincing evidence to recommend cl...
AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer...
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. Advise patients to immediately report cough, dyspnea, fever, and/o...
CTs were used in early lines for patients with visceral symptoms. Introduction Breast cancer (BC) is the most common cancer among women [1, 2]. It is also the second most common cause of cancer-related deaths in women globally [2], and the third leading cause o...
malignancies. Based on its mechanism of action, Braftovi may promote malignancies associated with activation of RAS through mutation or other mechanisms. Monitor patients receiving Braftovi for signs and symptoms of non-cutaneous malignancies. Discontinue Braftovi for RAS mutationp...